Cartography Biosciences

During #NationalColorectalCancerAwarenessMonth, we recognize the patients & families working to change the trajectory of colorectal cancer. We’re advancing CBI-1214, targeting LY6G6D, in a Phase 1 trial for MSS/MSI-L CRC to help expand treatment options for patients. #EnoughCRC

We’ve dosed the 1st patient in our Phase 1 trial of CBI-1214, targeting LY6G6D in MSS/MSI-L colorectal cancer. This milestone marks our clinic entry with a selectively engineered program advancing more precise options for hard-to-treat cancers. Read more: businesswire.com/news/home/2026…

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: How does biotech come from the lab bench? Kevin Parker, CEO of @CartographyBio, discusses how his PhD research spun out and advice for future biotech founders.

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Kevin Parker, CEO of @CartographyBio, shares where he sees the future of oncology research.

In a recent @BiotechTV conversation with Chloe Kirk, CEO Kevin Parker was asked when Cartography truly felt like it had hit its "aha" moment. His answer reflects a defining inflection point and the momentum that continues to carry us into the year ahead. Listen in below.

#ICYMI CEO Kevin Parker spoke with @ky_lahucik at @Endpts about the Pfizer deal announced earlier this week, including why Cartography’s platform continues to resonate with large pharma. Read more below. endpoints.news/cartography-do…

Read more: businesswire.com/news/home/2026…

We announced a strategic collaboration with @Pfizer with over $850M in potential value, reinforcing the strength & scalability of our ATLAS and SUMMIT platforms. The partnership supports near term execution & long term value creation, with CBI 1214 remaining wholly owned.

Wrapping up 2025, we’re grateful for meaningful progress at Cartography, including IND approval for CBI-1214, a step toward delivering more precise, tumor-targeted therapies to patients in need. Thank you to our team & partners for advancing our mission, & Happy New Year!

We've received FDA IND approval & Fast Track designation for CBI-1214, our lead T-cell engager for colorectal #cancer. These milestones support advancement into Phase 1 & address a significant unmet need in CRC. Read more: businesswire.com/news/home/2025…

#JPM26 is only one month away! We continue to advance our platform to uncover novel, tumor-selective targets & look forward to sharing more on our lead program, CBI-1214, which is progressing toward the clinic for patients with colorectal #cancer.

Five years ago, Cartography set out to accelerate #drugdiscovery through comprehensive antigen profiling & redefine how we target #cancer. We recently celebrated that milestone in Yosemite & now look ahead to bringing our first program, CBI-1214, into the clinic. Cheers, team!

#ICYMI CEO Kevin Parker spoke with @d_samorodnitsky at @biospace about how we're pushing single-cell sequencing to new limits, uncovering targets others can't see. Read the feature below. biospace.com/drug-developme…

Our $67M Series B is being celebrated on the Nasdaq Tower in Times Square! Thanks to @Nasdaq for recognizing this milestone & to our team & investors driving our mission to map #cancer biology & identify safer, more selective immunotherapy targets.

We're excited to share the close of our $67M Series B financing, which will enable us to advance our lead program into the clinic & continued acceleration of additional oncology programs from our drug discovery platforms. Our CEO shares more below. Details:businesswire.com/news/home/2025…

We're thrilled to welcome Dirk Nagorsen as CMO & Annie Winterhall as our Head of Clinical Operations.  Their clinical development & oncology experience will be instrumental as we prepare to enter the clinic with our lead program, CBI-1214. Details: businesswire.com/news/home/2025…

Our 2nd annual #ConvergeSummit will feature an engaging conversation between leaders from @CartographyBio, Genesis Therapeutics and @GileadSciences on the importance of collaboration for driving progress in tech and life science. Learn more: bit.ly/4hAjK8j

Cartography's CSO will join a panel discussion at the @biocom Converge Summit to discuss how pharma collaborations can accelerate innovation. We look forward to an engaging conversation that dives deep into the power of partnerships in driving breakthrough advancements.

March is #ColorectalCancerAwarenessMonth, a time to amplify awareness & advance the conversation around CRC. We're pioneering CB21, a next-generation therapy designed for MSS CRC patients. Learn more from organizations like @CCAlliance and visit our website for our approach.

Cartography is attending @biocom Global Life Science Partnering & Investor Conference to connect with industry leaders & investors to map the future of #precisionmedicine. We look forward to engaging in discussions & collaborations that will shape the next frontier of biotech.